In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor

Rationale The lack of potent, selective, brain penetrant Y 2 receptor antagonists has hampered in vivo functional studies of this receptor. Objective Here, we report the in vitro and in vivo characterization of JNJ-31020028 ( N -(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychopharmacology 2010-02, Vol.208 (2), p.265-277
Hauptverfasser: Shoblock, James R., Welty, Natalie, Nepomuceno, Diane, Lord, Brian, Aluisio, Leah, Fraser, Ian, Motley, S. Timothy, Sutton, Steve W., Morton, Kirsten, Galici, Ruggero, Atack, John R., Dvorak, Lisa, Swanson, Devin M., Carruthers, Nicholas I., Dvorak, Curt, Lovenberg, Timothy W., Bonaventure, Pascal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 277
container_issue 2
container_start_page 265
container_title Psychopharmacology
container_volume 208
creator Shoblock, James R.
Welty, Natalie
Nepomuceno, Diane
Lord, Brian
Aluisio, Leah
Fraser, Ian
Motley, S. Timothy
Sutton, Steve W.
Morton, Kirsten
Galici, Ruggero
Atack, John R.
Dvorak, Lisa
Swanson, Devin M.
Carruthers, Nicholas I.
Dvorak, Curt
Lovenberg, Timothy W.
Bonaventure, Pascal
description Rationale The lack of potent, selective, brain penetrant Y 2 receptor antagonists has hampered in vivo functional studies of this receptor. Objective Here, we report the in vitro and in vivo characterization of JNJ-31020028 ( N -(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y 2 receptor antagonist. Methods The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y 2 receptors in KAN-Ts cells and rat Y 2 receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y 2 bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release. Results JNJ-31020028 bound with high affinity (pIC 50  = 8.07 ± 0.05, human, and pIC 50  = 8.22 ± 0.06, rat) and was >100-fold selective versus human Y 1 , Y 4 , and Y 5 receptors. JNJ-31020028 was demonstrated to be an antagonist (pK B  = 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y 2 receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake. Conclusion These results suggest that Y 2 receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.
doi_str_mv 10.1007/s00213-009-1726-x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_218965365</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1935427661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c230x-4f20d6698eea0ed514fe40ce6b2a9f2eedeac60dbd2f02ae8fe6c29028ab82c33</originalsourceid><addsrcrecordid>eNp1UU1r3DAUFKWFbrf9Ab2JnjZQpU-S12sfS0jzQUgv7SGUYmT5OavglVxJXtYb-rdzjlwXeqoQiKd5M_OkIeQ9h1MOsPkUAASXDKBkfCNydnhBFjyTggnYiJdkASAlk3xdvCZvQniAtLIiW5CnK0v3JnpHlW2omYq9o3qrvNIRvTmqaJylrqXXt9dJAEQyKujqlq0y9pixH4KtGoNxO3ZqZ6w7YYK5g2Oc9Vu0Y_cH-dmbHr06Gpvux-43k6ztBufd3DNx-tGbJuEy4TXaYxJr8OQjVTRghzqaPdLaqzRgjxajVzbSsFNdR3cu4UOH6QFR3TtrQpzGjVukFofkgX1MWvSO3gnqUafS-bfkVau6gO_-nkvy_cv5t7NLdvP14urs8w3TQsKBZa2AJs_LAlEBNmuetZiBxrwWqmwFYoNK59DUjWhBKCxazLUo0w-puhBayiX5MOv23v0aMMTqwQ3eJstK8KLM1zLtJeFzk_YuBI9t1XuzU36sOFRTutWcbpXSraZ0q0PiiJkTUq-9R_9P-P-kZ4YNq6Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218965365</pqid></control><display><type>article</type><title>In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor</title><source>SpringerLink Journals</source><creator>Shoblock, James R. ; Welty, Natalie ; Nepomuceno, Diane ; Lord, Brian ; Aluisio, Leah ; Fraser, Ian ; Motley, S. Timothy ; Sutton, Steve W. ; Morton, Kirsten ; Galici, Ruggero ; Atack, John R. ; Dvorak, Lisa ; Swanson, Devin M. ; Carruthers, Nicholas I. ; Dvorak, Curt ; Lovenberg, Timothy W. ; Bonaventure, Pascal</creator><creatorcontrib>Shoblock, James R. ; Welty, Natalie ; Nepomuceno, Diane ; Lord, Brian ; Aluisio, Leah ; Fraser, Ian ; Motley, S. Timothy ; Sutton, Steve W. ; Morton, Kirsten ; Galici, Ruggero ; Atack, John R. ; Dvorak, Lisa ; Swanson, Devin M. ; Carruthers, Nicholas I. ; Dvorak, Curt ; Lovenberg, Timothy W. ; Bonaventure, Pascal</creatorcontrib><description>Rationale The lack of potent, selective, brain penetrant Y 2 receptor antagonists has hampered in vivo functional studies of this receptor. Objective Here, we report the in vitro and in vivo characterization of JNJ-31020028 ( N -(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y 2 receptor antagonist. Methods The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y 2 receptors in KAN-Ts cells and rat Y 2 receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y 2 bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release. Results JNJ-31020028 bound with high affinity (pIC 50  = 8.07 ± 0.05, human, and pIC 50  = 8.22 ± 0.06, rat) and was &gt;100-fold selective versus human Y 1 , Y 4 , and Y 5 receptors. JNJ-31020028 was demonstrated to be an antagonist (pK B  = 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y 2 receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake. Conclusion These results suggest that Y 2 receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-009-1726-x</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Antagonist drugs ; Biomedical and Life Sciences ; Biomedicine ; Neurosciences ; Neurotransmitters ; Original Investigation ; Pharmacology/Toxicology ; Psychiatry ; Psychopharmacology ; Rodents</subject><ispartof>Psychopharmacology, 2010-02, Vol.208 (2), p.265-277</ispartof><rights>Johnson and Johnson Pharmaceutical Research and Development, L.L.C. 2009</rights><rights>Springer-Verlag 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c230x-4f20d6698eea0ed514fe40ce6b2a9f2eedeac60dbd2f02ae8fe6c29028ab82c33</citedby><cites>FETCH-LOGICAL-c230x-4f20d6698eea0ed514fe40ce6b2a9f2eedeac60dbd2f02ae8fe6c29028ab82c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-009-1726-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-009-1726-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Shoblock, James R.</creatorcontrib><creatorcontrib>Welty, Natalie</creatorcontrib><creatorcontrib>Nepomuceno, Diane</creatorcontrib><creatorcontrib>Lord, Brian</creatorcontrib><creatorcontrib>Aluisio, Leah</creatorcontrib><creatorcontrib>Fraser, Ian</creatorcontrib><creatorcontrib>Motley, S. Timothy</creatorcontrib><creatorcontrib>Sutton, Steve W.</creatorcontrib><creatorcontrib>Morton, Kirsten</creatorcontrib><creatorcontrib>Galici, Ruggero</creatorcontrib><creatorcontrib>Atack, John R.</creatorcontrib><creatorcontrib>Dvorak, Lisa</creatorcontrib><creatorcontrib>Swanson, Devin M.</creatorcontrib><creatorcontrib>Carruthers, Nicholas I.</creatorcontrib><creatorcontrib>Dvorak, Curt</creatorcontrib><creatorcontrib>Lovenberg, Timothy W.</creatorcontrib><creatorcontrib>Bonaventure, Pascal</creatorcontrib><title>In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><description>Rationale The lack of potent, selective, brain penetrant Y 2 receptor antagonists has hampered in vivo functional studies of this receptor. Objective Here, we report the in vitro and in vivo characterization of JNJ-31020028 ( N -(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y 2 receptor antagonist. Methods The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y 2 receptors in KAN-Ts cells and rat Y 2 receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y 2 bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release. Results JNJ-31020028 bound with high affinity (pIC 50  = 8.07 ± 0.05, human, and pIC 50  = 8.22 ± 0.06, rat) and was &gt;100-fold selective versus human Y 1 , Y 4 , and Y 5 receptors. JNJ-31020028 was demonstrated to be an antagonist (pK B  = 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y 2 receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake. Conclusion These results suggest that Y 2 receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.</description><subject>Antagonist drugs</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Neurosciences</subject><subject>Neurotransmitters</subject><subject>Original Investigation</subject><subject>Pharmacology/Toxicology</subject><subject>Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rodents</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1UU1r3DAUFKWFbrf9Ab2JnjZQpU-S12sfS0jzQUgv7SGUYmT5OavglVxJXtYb-rdzjlwXeqoQiKd5M_OkIeQ9h1MOsPkUAASXDKBkfCNydnhBFjyTggnYiJdkASAlk3xdvCZvQniAtLIiW5CnK0v3JnpHlW2omYq9o3qrvNIRvTmqaJylrqXXt9dJAEQyKujqlq0y9pixH4KtGoNxO3ZqZ6w7YYK5g2Oc9Vu0Y_cH-dmbHr06Gpvux-43k6ztBufd3DNx-tGbJuEy4TXaYxJr8OQjVTRghzqaPdLaqzRgjxajVzbSsFNdR3cu4UOH6QFR3TtrQpzGjVukFofkgX1MWvSO3gnqUafS-bfkVau6gO_-nkvy_cv5t7NLdvP14urs8w3TQsKBZa2AJs_LAlEBNmuetZiBxrwWqmwFYoNK59DUjWhBKCxazLUo0w-puhBayiX5MOv23v0aMMTqwQ3eJstK8KLM1zLtJeFzk_YuBI9t1XuzU36sOFRTutWcbpXSraZ0q0PiiJkTUq-9R_9P-P-kZ4YNq6Y</recordid><startdate>201002</startdate><enddate>201002</enddate><creator>Shoblock, James R.</creator><creator>Welty, Natalie</creator><creator>Nepomuceno, Diane</creator><creator>Lord, Brian</creator><creator>Aluisio, Leah</creator><creator>Fraser, Ian</creator><creator>Motley, S. Timothy</creator><creator>Sutton, Steve W.</creator><creator>Morton, Kirsten</creator><creator>Galici, Ruggero</creator><creator>Atack, John R.</creator><creator>Dvorak, Lisa</creator><creator>Swanson, Devin M.</creator><creator>Carruthers, Nicholas I.</creator><creator>Dvorak, Curt</creator><creator>Lovenberg, Timothy W.</creator><creator>Bonaventure, Pascal</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>201002</creationdate><title>In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor</title><author>Shoblock, James R. ; Welty, Natalie ; Nepomuceno, Diane ; Lord, Brian ; Aluisio, Leah ; Fraser, Ian ; Motley, S. Timothy ; Sutton, Steve W. ; Morton, Kirsten ; Galici, Ruggero ; Atack, John R. ; Dvorak, Lisa ; Swanson, Devin M. ; Carruthers, Nicholas I. ; Dvorak, Curt ; Lovenberg, Timothy W. ; Bonaventure, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c230x-4f20d6698eea0ed514fe40ce6b2a9f2eedeac60dbd2f02ae8fe6c29028ab82c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antagonist drugs</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Neurosciences</topic><topic>Neurotransmitters</topic><topic>Original Investigation</topic><topic>Pharmacology/Toxicology</topic><topic>Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rodents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shoblock, James R.</creatorcontrib><creatorcontrib>Welty, Natalie</creatorcontrib><creatorcontrib>Nepomuceno, Diane</creatorcontrib><creatorcontrib>Lord, Brian</creatorcontrib><creatorcontrib>Aluisio, Leah</creatorcontrib><creatorcontrib>Fraser, Ian</creatorcontrib><creatorcontrib>Motley, S. Timothy</creatorcontrib><creatorcontrib>Sutton, Steve W.</creatorcontrib><creatorcontrib>Morton, Kirsten</creatorcontrib><creatorcontrib>Galici, Ruggero</creatorcontrib><creatorcontrib>Atack, John R.</creatorcontrib><creatorcontrib>Dvorak, Lisa</creatorcontrib><creatorcontrib>Swanson, Devin M.</creatorcontrib><creatorcontrib>Carruthers, Nicholas I.</creatorcontrib><creatorcontrib>Dvorak, Curt</creatorcontrib><creatorcontrib>Lovenberg, Timothy W.</creatorcontrib><creatorcontrib>Bonaventure, Pascal</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shoblock, James R.</au><au>Welty, Natalie</au><au>Nepomuceno, Diane</au><au>Lord, Brian</au><au>Aluisio, Leah</au><au>Fraser, Ian</au><au>Motley, S. Timothy</au><au>Sutton, Steve W.</au><au>Morton, Kirsten</au><au>Galici, Ruggero</au><au>Atack, John R.</au><au>Dvorak, Lisa</au><au>Swanson, Devin M.</au><au>Carruthers, Nicholas I.</au><au>Dvorak, Curt</au><au>Lovenberg, Timothy W.</au><au>Bonaventure, Pascal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><date>2010-02</date><risdate>2010</risdate><volume>208</volume><issue>2</issue><spage>265</spage><epage>277</epage><pages>265-277</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale The lack of potent, selective, brain penetrant Y 2 receptor antagonists has hampered in vivo functional studies of this receptor. Objective Here, we report the in vitro and in vivo characterization of JNJ-31020028 ( N -(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y 2 receptor antagonist. Methods The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y 2 receptors in KAN-Ts cells and rat Y 2 receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y 2 bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release. Results JNJ-31020028 bound with high affinity (pIC 50  = 8.07 ± 0.05, human, and pIC 50  = 8.22 ± 0.06, rat) and was &gt;100-fold selective versus human Y 1 , Y 4 , and Y 5 receptors. JNJ-31020028 was demonstrated to be an antagonist (pK B  = 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y 2 receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake. Conclusion These results suggest that Y 2 receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><doi>10.1007/s00213-009-1726-x</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacology, 2010-02, Vol.208 (2), p.265-277
issn 0033-3158
1432-2072
language eng
recordid cdi_proquest_journals_218965365
source SpringerLink Journals
subjects Antagonist drugs
Biomedical and Life Sciences
Biomedicine
Neurosciences
Neurotransmitters
Original Investigation
Pharmacology/Toxicology
Psychiatry
Psychopharmacology
Rodents
title In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A49%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20and%20in%20vivo%20characterization%20of%20JNJ-31020028%20(N-(4-%7B4-%5B2-(diethylamino)-2-oxo-1-phenylethyl%5Dpiperazin-1-yl%7D-3-fluorophenyl)-2-pyridin-3-ylbenzamide),%20a%20selective%20brain%20penetrant%20small%20molecule%20antagonist%20of%20the%20neuropeptide%20Y%20Y2%20receptor&rft.jtitle=Psychopharmacology&rft.au=Shoblock,%20James%20R.&rft.date=2010-02&rft.volume=208&rft.issue=2&rft.spage=265&rft.epage=277&rft.pages=265-277&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-009-1726-x&rft_dat=%3Cproquest_cross%3E1935427661%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218965365&rft_id=info:pmid/&rfr_iscdi=true